No Data
Market Might Still Lack Some Conviction On Changmao Biochemical Engineering Company Limited (HKG:954) Even After 25% Share Price Boost
CHANGMAO BIO: INTERIM REPORT 2024
CITIC Securities: How to look forward to the future of the csi sws food & beverage index & liquor sector in the mid-term report?
CITIC Securities released a research report stating that the Q2 light meal chain industry continues to show weak demand, with pressure on store efficiency and expansion.
Changmao Bio (00954.HK) had a mid-year sales revenue of approximately 0.314 billion yuan, a year-on-year increase of about 5.8%.
Changmao Bio (00954.HK) announced that for the six months ended June 30, 2024, the group's sales revenue was RMB 313,802,000, an increase of about 5.8% from RMB 296,608,000 in the same period last year; the net loss attributable to shareholders of the company was approximately RMB 18,786,000. The net income attributable to shareholders of the company in the same period last year was approximately RMB 4,157,000.
Changmao Bio (00954) announced its interim results and the shareholders' losses amounted to 18.786 million yuan, a year-on-year loss of profit.
Changmao Bio (00954) announced its mid-term performance for 2024, with revenue of about 0.314 billion yuan, a year-on-year increase of about 5.8%...
CHANGMAO BIO: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 2024
Market Cool On Changmao Biochemical Engineering Company Limited's (HKG:954) Revenues Pushing Shares 28% LowerNo Data
No Data
